Aspen Pharmacare Holdings Limited · JSE:APN
Aspen Pharmacare — Investor Day (2023)
57 slides from Aspen Pharmacare's investor day presentation, 2023
Slide 1: Capital Markets Day 2023 – NDB Site Visit
CAPITAL MARKETS Day 2023 ey ASPEN | NDB Site Visit
Slide 2: Disclaimer
DISCLAIMER CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.
Slide 3: Background and Objective
Stephen Saad Group Chief Executive BACKGROUND AND OBJECTIVE
Slide 4: Capital Markets Day: Background and Objectives
Capital Markets Day BACKGROUND AND OBJECTIVES o cal Insights into Our Manufacturing Expertise Opportunities created Demonstration of confidence in our ability to execute on them Settled Foundation Period of aggressive globalisation ai of business Scars and stars from the many lessons learnt Poised f
Slide 5: Aspen's Strategic Journey in Sterile Manufacturing
ASPEN’S STRATEGIC JOURNEY IN STERILE MANUFACTURING
Slide 6: Vision for Sterile Manufacturing
Vision For Sterile Manufacturing 8 YEARS IN THE MAKING Sustainable demand AREAS OF INVESTMENT Future shift towards biologicals First mover • Prefilled syringes and other advanced sterile strategic advantage technologies. • Anaesthetics Opportunity to increase • Vaccines & biologicals Vertical integr
Slide 7: Patient Access & Commercial Imperatives - A Symbiotic Relationship
Patient Access & Commercial Impertatives - A Symbiotic Relationship INCREASING PATIENT ACCESS PROVIDES THE FOUNDATION FOR SUSTAINABLE VOLUMES Strong Global Pharma Partnerships Alliances with governments and multilateral agencies ACCESS A CORE STRATEGY FOR 25 YEARS [eKee) Skilled and highly capable 6
Slide 8: Ensuring Patient Access in Challenging Circumstances
Ensuring Patient Access in Challenging Circumstances OUR TIMELINE JOURNEY MDR TB PAEDIATRIC VACCINES Serum Partnership © Aspens first sterile facility investment © Partnership with Lilly for Capreomycin © Endorsed by GAVI © Grant funding from BMGF and CEPI ©@ WHO endorsed programme 2007 2023 COT g =
Slide 9: Anaesthetics
Anaesthetics KEY ENABLER IN BUILDING ASPEN’S STERILE MANUFACTURING FOUNDATION Insourcing Strategy R5.6BN Capex Investment STRATEGIC VISION AS GUIDED SINCE 2020: VALUE SITS IN SPARE CAPACITY TO DRIVE SUPERIOR ROIC
Slide 10: Building the Aspen NDB Prefilled Syringe House
Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND COMMERCIAL TRANSACTIONS GSK Thrombosis products (Arixtra & Fraxiparine) including Aspen NDB facility -2014 Mono-embolex Thrombosis product from Novartis in 2015
Slide 11: Building the Aspen NDB Prefilled Syringe House
Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND RESHAPING AND EXPANDING CAPACITY CE
Slide 12: Building the Aspen NDB Prefilled Syringe House
Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND
Slide 13: Building the Aspen NDB Prefilled Syringe House: New Contracts 2023
Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND NEW CONTRACTS SECURED IN 2023 | INCLUDING mRNA TECHNOLOGY
Slide 14: Building the Aspen NDB Prefilled Syringe House: Future Opportunities
Building the Aspen NDB Prefilled Syringe House IMMEDIATELY AVAILABLE PFS CAPACITY TO MEET INCREASED DEMAND FUTURE OPPORTUNITIES
Slide 15: Building the South African Sterile Houses: Suite 1
Building the South African Sterile Houses SUITE 1: THE ORIGINAL HOUSE 2007 ONWARDS
Slide 16: Building the South African Sterile Houses: Insourcing Anaesthetics
Building the South African Sterile Houses INSOURCING ANAESTHETICS 2019-2026 Basis for new Sterile Facility investment (suite 2) Built at the highest spec to include vaccines and other biologicals
Slide 17: Building the South African Sterile Houses: J&J COVID Vaccine
Building the South African Sterile Houses J&J COVID VACCINE 2020 225m doses supplied Aspen on global stage
Slide 18: Building the South African Sterile Houses: Serum Agreement
EN Building the Spent African Sterile Houses UM AGREEM
Slide 19: Building the South African Sterile Houses: Novo Agreement
Building the South African Sterile Houses NOVO AGREEMENT 2023 !
Slide 20: Building the South African Sterile Houses: Future Opportunities
Building the South African Ster FUTURE OPPURTUNITIES
Slide 21: Strong Medium Term Growth Outlook for Steriles
8 Years On – Harvesting Stage STRONG MEDIUM TERM GROWTH OUTLOOK FOR STERILES FY27 - Additional upside potential FY29 R10bn Sterile FY26 target Capex spend incremental NHEPS R4.0bn contribution >R5.50/share FY26 R0.8bn anaesthetics insourcing Increased FCF from WCap light R3.0bn to 3.5bn contribution
Slide 22: Insights into SA Operations
Martin Pretorius Integration Director INSIGHTS INTO SA OPERATIONS
Slide 23: South African Operation
South African Operation ASPEN’S HERITAGE CAN BE TRACED BACK TO A BUSINESS WHICH COMMENCED TRADE IN PORT ELIZABETH IN 1850
Slide 24: South African Operations: Capabilities & Capacities
South African Operations: Capabilities & Capacities STERILE CAPACITIES: FILLING LINE CAPABILITY Vials (space for 3 more vial filling lines) Capabilities Ampoules Eyedrops Vial Vial/cartridge Vial Vial Capacity 2 lines 2 lines 1 line 1 line 1 line 2 lines Use Anaesthetics Exported to Anaesthetics Nov
Slide 25: Sterile Capacity Expansion
Sterile Capacity Expansion 1 _ . Single sterile platform meeting n Aim is to create synergy in ways of - global standards ! working, best practice implementation ! and leveraging the existing sterile presence 1 1 EQUIPMENT AND DESIGN PROCESS BASIC OPERATING PRINCIPLES SYNONYMOUS WITH WORLD CLASS STE
Slide 26: Sterile Manufacturing: Value Proposition
Sterile Manufacturing: Value Proposition CUSTOMISING ANAESTHETIC FACILITY TO CATER FOR INSULINS AND ANAESTHETICS
Slide 27: ESG Initiatives: SA Operations
ESG Initiatives: SA Operations SECURING SUPPLY WHILST POSITIVELY IMPACTING THE ENVIRONMENT Water Sustainability Steam Generation
Slide 28: Water Sustainability
Water Sustainability WATER CONSUMPTION CURRENT USAGE IS 800K LITRES/DAY Short Term 750k litres/day from borehole and water treatment plant Medium Term (18 months) Second borehole and treatment plant extension Long Term End state will be about 1 500k litres/day
Slide 29: Steam Generation
Steam Generation In line with the Group’s ESG goals; in 2021 we implemented a steam generation project to convert from heavy fuels to biomass for steam generation Benefits include: Emissions - 10 times less than current SA legal standard Reduction in CO2 emissions — approximately 8 500 tonnes/year ®
Slide 30: Energy
Energy ENSURING SUSTAINABLE COST-EFFECTIVE ELECTRICITY SUPPLY Short Term Rental diesel back-up power generation synchronized with the municipal supply ’ Medium Term (2025) 20 MW Refuse derived fuel (RDF) power generation plant, will be sufficient to be completely off the grid. » Full electricity sec
Slide 31: Insights into NDB Operations
INSIGHTS INTO NDB OPERATIONS
Slide 32: NDB: Through The Ages
NDB: Through The Ages
Slide 33: NDB: Site Facilities
NDB: Site Facilities |____ 3 API workshops : ie Certopatine, Nadroparine Fondaparinux PFS Production : Filling, & Inspection and Packaging a) BFS Production : Filling, Inspection and Packaging }é Laboratories Warehouse > Here we are A Spots of visit
Slide 34: NDB: Site Facilities
NDB: Site Facilities Prefilled Syringe Blow Fill Seal Anticoagulant API’s Anticoagulants Polyamps PE © O @ Diluents O Polyamps PP O mRNA Technology O Polybags © © Flu Vaccines Tech Transfer
Slide 35: NDB: PFS Capacity
NDB: PFS Capacity 3 PFS Lines with a Total of 350M Capacity 4 Inspection Lines 6 Packaging Lines © Committed and Current e Available
Slide 36: NDB Capacities: BFS Rotary Filling Machines
NDB Capacities: BFS 2 Rotary Filling Machines Total Capacity of 50 million 1 Filling Machine for Rigid Bags 3 Automated Leak Detection and Visual Inspection Lines 3 Terminal Autoclaves 2 Packaging Lines
Slide 37: NDB Capacities: Laboratories & Warehouse
NDB Capacities: Laboratories & Warehouse QUALITY AND TESTING 3 Divis = ° wr SS . e Wh \\ eP / O
Slide 38: ESG Investment For A Sustainable Future
ESG Investment For A Sustainable Future SECURING SUPPLY WHILST POSITIVELY IMPACTING THE ENVIRONMENT 40
Slide 39: ESG Investment: Reduction in Water Consumption
ESG Investment For A Sustainable Future REDUCTION IN WATER CONSUMPTION Two main changes in the water consumption reduction: Evolution of water consumption (m3) • Former filling building stopped and filling activities transferred in the new building T – Implementation of new recycling cleaning water
Slide 40: ESG Investment: Lower GHG Emissions
ESG Investment for Sustainable Future LOWER GHG EMISSIONS FY Actions Annual target FY24. Solar panel & Heat recovery BFS -5% FY25 Hot water system replacement (buid $/P) = 3% FY26 Biomass (boiler replacement) 48% FY27 Restaurant boiler replacement -1% FY28_ Heat recovery on chillers (buid 7) -3% FY2
Slide 41: Defining Operational Excellence
DEFINING OPERATIONAL EXCELLENCE
Slide 42: Aspen Sterile Manufacturing Operations
Aspen Sterile Manufacturing Operations
Slide 43: Quality By Design
Quality By Design A STRATEGIC APPROACH Non-negotiable in the pharmaceutical industry Compliance assured on an on-going basis @ Internal controls | _ 7 @ Regulators Behind every medicine lies an Pars @ Customers, supplier and intricate process, where ne prospective clients' audits precision and excel
Slide 44: Demonstration of Quality: Fondaparinux API
Demonstration of Quality FONDAPARINUX API Ensuring absence of chemical contaminants Assurance of purity @) Continuous improvement 65% PURITY PURIFIED PRODUCT PURE VS IMPURE TEST s =
Slide 45: Demonstration of Quality
Demonstration of Quality Y) Absence of physical contamination Gj Glass particles and glass delamination Ejected glass particle CQ Assurance of absence of particles in sterile products
Slide 46: Our Sterile Operations Value Proposition
Our Sterile Operations Value Proposition QUALITY FIRST AND FOREMOST CONSIDERATION OF OUR CUSTOMERS Quality is a core responsibility of any company. Healthcare providers, patients, consumers and customers expect the level of quality they are promised. By building quality into processes, a company mee
Slide 47: Our Sterile Operations Value Proposition: We Make It Happen
Our Sterile Operations Value Proposition WE MAKE IT HAPPEN Customer Recognition of Capability @ J&J called Aspen the ‘Jewel in the J&J crown’ during the Covid vaccine partnerships. ‘At the end of a very challenging year we wish to express our sincere thanks to the entire Aspen team for the exception
Slide 48: The Aspen Value Proposition
The Aspen Value Proposition EXECUTING ON OUR CAPACITY FILL STRATEGY A Jud llaborati ra Johnson & Johnson Announces spen concludes a collaboration agreement to i manufacture and make available four Aspen- Landmark Agreement to Enable its branded vaccines for Africa. COVID-19 Vaccine to be Manufacture
Slide 49: Technical Transfer Testimony
TECHNICAL TRANSFER TESTIMONY
Slide 50: COVID-19 Technical Transfer
Slide 51: Stephen Saad
Stephen Saad Group Chief Executive
Slide 52: Recap of Aspen Strategic Focus
Recap of Aspen Strategic Focus al Commercial Pharma ex-China fifall © Settled business with high predictability @ Sustained organic performance @ Supplemented by transactions that leverage our current footprint @ Future pipelines also included: LATAM product portfolio and Lilly transactions cleared}
Slide 53: Recap of Aspen Strategic Focus: Manufacturing
Recap of Aspen Strategic Focus MANUFACTURING Critical success factor to our strategic vision and ambitions @ In spite of being a third of the size of Commercial Pharma @ Both commercially and socially @ Gives us the capability to enhance equitable access Fundamental shift in return on assets and mat
Slide 54: Why Aspen?
Why Aspen? PUNCHING WAY ABOVE OUR WEIGHT TO DELIVER ACCESS g o ©} sspeno First FDA MDR TB Over 1,000,000 225m COVID doses Realisation of Generic ARV HIV/ AIDS patients for Africa African ambition reached in Africa 3 : ny ° ny Kk Manufactured COVID Manufactured both 1st & 2nd line TB treatments vacci
Slide 55: Sterile Manufacturing: Why Aspen?
Sterile Manufacturing: Why Aspen? CLIENT BASE OF PHARMA GIANTS -AN ENDORSEMENT OF CAPABILITY AND PROCESS INTEGRITY Aspen is Highly Regarded @ Supported by historic and current customer base @ Our customer base represent some of the giants at the cutting edge of global pharma @ Every major multinatio
Slide 56: Why Aspen - Future Opportunities?
Why Aspen-Future Opportunities? RIGHT PLACE AT THE RIGHT TIME, WITH THE RIGHT CAPABILITIES © @ The increases in sterile demand for cartridges/prefilled syringe capabilities is unprecedented @ Machinery suppliers need more than 24 months Obesity/diabetes markets will need billions of weekly sterile d
Slide 57: Why Aspen - It's in the DNA?
Why Aspen - It’s in The DNA? Successful execution is fundamental to Manufacturing excellence is in our DNA delivering on existing and future opportunities Full focus on delivery of existing opportunities. Its not glamorous and glitzy, its more like scrumming Dark art, spending honest endeavour, push